At Novo Nordisk, we believe that experiments on living animals should
only be conducted when no other suitable alternative methods are
available, and the anticipated benefits to humans must balance the
harm to the animals.
While we cannot foresee replacing all animal experiments in the near
future, we continuously refine the housing, care, and use of animals.
We also develop new methods and technologies that don't involve
animals, such as computer simulations, tissue cultures, and cell-based methods.
Over the last decade, Novo Nordisk has reduced the number of
experimental animals used per individual project due to improvements.
The total number of animals used at Novo Nordisk depends on the
number of projects in our overall research and development pipeline,
including projects related to companies which we have acquired.
Several factors determine how many animals Novo Nordisk requires in a
given year, such as the number, nature, and development phases of new
pharmaceuticals, regulatory requirements, and the development of
validated new methods that can reduce or replace the use of animals.
Novo Nordisk continually strives to reduce the number of animals
used. However, due to the company's significant growth and increased
research activities, the total number of animals needed is likely to increase.
Animal experiments play a crucial role in our efforts to investigate
the effects of a new drug candidate in the body, as well as
identifying potential side effects. These are health authority
requirements before the drug can be administered to humans.
We also use animals to gain a better understanding of the causes and
effects of diseases, and how we can find new treatment methods or even
At Novo Nordisk, it's important for us to act with due respect for
the animals by establishing and ensuring high ethical and welfare
standards. We support transparency and openness about animal
experimentation and will continue to report on our use of experimental animals.
Novo Nordisk's position on animal experimentation
1) Reduce, Refine and Replace
Novo Nordisk supports the
principles of the Three Rs (Reduce, Refine and Replace) and is
integrating these principles in all our processes and procedure.
2) Internal ethical standards
Novo Nordisk supports high ethical standards in relation to animal
experimentation and performs an internal ethical review of all new
types of experiments on animals
3) External ethical standards
Novo Nordisk acknowledges its responsibilities in relation to
experiments on living animals carried out by external parties on
behalf of Novo Nordisk and supports high ethical and welfare standards
at our external partners, contract research organisations and
suppliers and monitors their performance
4) Use of non-human primates
Novo Nordisk acknowledges the specific concern about the use of
non-human primates and supports that all experiments on non-human
primates are thoroughly evaluated and special attention is paid to the
housing, training and socialisation as well as the source of non-human primates
5) High animal welfare standards
Novo Nordisk supports high animal welfare standards in relation
to the housing, care and use of experimental animals and will house
the animals according to their needs, provide appropriate training and
socialisation of the animals
6) Use of animal models
Novo Nordisk is aware of the specific concern about the use of
animal models of human disease including the use of transgenic animals
and the importance of considering and minimising the welfare impact on
7) Experiments on living animals
Novo Nordisk supports the principle that experiments on living
animals are properly regulated, and that the ethical and welfare
aspects of the use of experimental animal are adequately addressed in
national and international legislation